Table 2.
Antibiotic susceptibility profile of isolated Pseudomonas aeruginosa strains
| Class | Antibiotics | Percentage ofresistant isolates | Percentage of sensitive isolates | MICμg/ml | |
|---|---|---|---|---|---|
| Cephalosporins | (2G) Cefoxitin | 97.90% | 2.1% | ND* | |
| (3G) Ceftriaxone | 74.74% | 25.26% | ND | ||
| (3G) Cefotaxime | 76% | 24% | ≥ 64 | ||
| (3G) Ceftazidime | 98.95% | 1.05% | ≥ 64 | ||
| (4G) Cefepime | 75.80% | 24.20% | ≥ 64 | ||
| penicillins/ | Ampicillin group | Amoxicillin/clavulanic acid | 88.4% | 11.6% | ND |
| ß-lactamase inhibitors | Ampicillin/sulbactam | 100% | 0 | ND | |
| Piperacillin group | Piperacillin | 72.6% | 27.4% | ND | |
| Piperacillin / tazobactam | 69.5% | 30.5% | ≥ 128 | ||
| Monobactams | Aztreonam | 82.11% | 17.89% | ND | |
| Carbapenems | Imipenem | 68.40% | 31.60% | ≥ 16 | |
| Meropenem | 68.40% | 31.60% | ≥ 16 | ||
| Lipopeptides | Colistin | 7.40% | 92.60% | ND | |
| Aminoglycosides | Gentamicin | 68.40% | 31.60% | ≥ 16 | |
| Amikacin | 69.48% | 30.52% | ≥ 64 | ||
| Fluoroquinolones | Ciprofloxacin | 71.60% | 28.40% | ≥ 4 |
ND* not determined